Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Discovery of a lead series of potent benzodiazepine 5-HT2C receptor agonists with high selectivity in functional and binding assays.

Ren A, Zhu X, Feichtinger K, Lehman J, Kasem M, Schrader TO, Wong A, Dang H, Le M, Frazer J, Unett DJ, Grottick AJ, Whelan KT, Morgan ME, Sage CR, Semple G.

Bioorg Med Chem Lett. 2020 Mar 1;30(5):126929. doi: 10.1016/j.bmcl.2019.126929. Epub 2019 Dec 26.

PMID:
31952960
2.

Angiotensin (1-7) does not interact directly with MAS1, but can potently antagonize signaling from the AT1 receptor.

Gaidarov I, Adams J, Frazer J, Anthony T, Chen X, Gatlin J, Semple G, Unett DJ.

Cell Signal. 2018 Oct;50:9-24. doi: 10.1016/j.cellsig.2018.06.007. Epub 2018 Jun 19.

PMID:
29928987
3.

Embelin and its derivatives unravel the signaling, proinflammatory and antiatherogenic properties of GPR84 receptor.

Gaidarov I, Anthony T, Gatlin J, Chen X, Mills D, Solomon M, Han S, Semple G, Unett DJ.

Pharmacol Res. 2018 May;131:185-198. doi: 10.1016/j.phrs.2018.02.021. Epub 2018 Feb 19.

PMID:
29471103
4.

Discovery of APD371: Identification of a Highly Potent and Selective CB2 Agonist for the Treatment of Chronic Pain.

Han S, Thoresen L, Jung JK, Zhu X, Thatte J, Solomon M, Gaidarov I, Unett DJ, Yoon WH, Barden J, Sadeque A, Usmani A, Chen C, Semple G, Grottick AJ, Al-Shamma H, Christopher R, Jones RM.

ACS Med Chem Lett. 2017 Nov 30;8(12):1309-1313. doi: 10.1021/acsmedchemlett.7b00396. eCollection 2017 Dec 14.

5.

Discovery of 2-(((1r,4r)-4-(((4-Chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralinepag): An Orally Active Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.

Tran TA, Kramer B, Shin YJ, Vallar P, Boatman PD, Zou N, Sage CR, Gharbaoui T, Krishnan A, Pal B, Shakya SR, Garrido Montalban A, Adams JW, Ramirez J, Behan DP, Shifrina A, Blackburn A, Leakakos T, Shi Y, Morgan M, Sadeque A, Chen W, Unett DJ, Gaidarov I, Chen X, Chang S, Shu HH, Tung SF, Semple G.

J Med Chem. 2017 Feb 9;60(3):913-927. doi: 10.1021/acs.jmedchem.6b00871. Epub 2017 Jan 19.

PMID:
28072531
6.

Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT2C receptor.

Schrader TO, Kasem M, Ren A, Feichtinger K, Al Doori B, Wei J, Wu C, Dang H, Le M, Gatlin J, Chase K, Dong J, Whelan KT, Sage C, Grottick AJ, Semple G.

Bioorg Med Chem Lett. 2016 Dec 15;26(24):5877-5882. doi: 10.1016/j.bmcl.2016.11.016. Epub 2016 Nov 9.

PMID:
27864071
7.

Promoting lifestyle behaviour change and well-being in hospital patients: a pilot study of an evidence-based psychological intervention.

Gate L, Warren-Gash C, Clarke A, Bartley A, Fowler E, Semple G, Strelitz J, Dutey P, Tookman A, Rodger A.

J Public Health (Oxf). 2016 Sep;38(3):e292-e300. Epub 2015 Oct 16.

PMID:
26476440
8.

Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.

Han S, Narayanan S, Kim SH, Calderon I, Zhu X, Kawasaki A, Yue D, Lehmann J, Wong A, Buzard DJ, Semple G, Carroll C, Chu ZL, Al-Sharmma H, Shu HH, Tung SF, Unett DJ, Behan DP, Yoon WH, Morgan M, Usmani KA, Chen C, Sadeque A, Leonard JN, Jones RM.

Bioorg Med Chem Lett. 2015 Aug 1;25(15):3034-8. doi: 10.1016/j.bmcl.2015.04.102. Epub 2015 May 23.

PMID:
26048791
9.

Discovery of a new series of potent prostacyclin receptor agonists with in vivo activity in rat.

Tran TA, Shin YJ, Kramer B, Choi J, Zou N, Vallar P, Martens P, Boatman PD, Adams JW, Ramirez J, Shi Y, Morgan M, Unett DJ, Chang S, Shu HH, Tung SF, Semple G.

Bioorg Med Chem Lett. 2015 Mar 1;25(5):1030-5. doi: 10.1016/j.bmcl.2015.01.024. Epub 2015 Jan 22.

PMID:
25666818
10.

(7-Benzyloxy-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic Acids as S1P1 Functional Antagonists.

Buzard DJ, Lopez L, Moody J, Kawasaki A, Schrader TO, Kasem M, Johnson B, Zhu X, Thoresen L, Kim SH, Gharbaoui T, Sengupta D, Calvano L, Krishnan A, Gao Y, Semple G, Edwards J, Barden J, Morgan M, Usmani K, Chen C, Sadeque A, Chen W, Christopher RJ, Thatte J, Fu L, Solomon M, Whelan K, Al-Shamma H, Gatlin J, Gaidarov I, Anthony T, Le M, Unett DJ, Stirn S, Blackburn A, Behan DP, Jones RM.

ACS Med Chem Lett. 2014 Nov 25;5(12):1334-9. doi: 10.1021/ml500422m. eCollection 2014 Dec 11.

11.

Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.

Buzard DJ, Kim SH, Lopez L, Kawasaki A, Zhu X, Moody J, Thoresen L, Calderon I, Ullman B, Han S, Lehmann J, Gharbaoui T, Sengupta D, Calvano L, Montalban AG, Ma YA, Sage C, Gao Y, Semple G, Edwards J, Barden J, Morgan M, Chen W, Usmani K, Chen C, Sadeque A, Christopher RJ, Thatte J, Fu L, Solomon M, Mills D, Whelan K, Al-Shamma H, Gatlin J, Le M, Gaidarov I, Anthony T, Unett DJ, Blackburn A, Rueter J, Stirn S, Behan DP, Jones RM.

ACS Med Chem Lett. 2014 Nov 4;5(12):1313-7. doi: 10.1021/ml500389m. eCollection 2014 Dec 11.

12.

Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonists.

Han S, Thoresen L, Zhu X, Narayanan S, Jung JK, Strah-Pleynet S, Decaire M, Choi K, Xiong Y, Yue D, Semple G, Thatte J, Solomon M, Fu L, Whelan K, Al-Shamma H, Gatlin J, Chen R, Dang H, Pride C, Gaidarov I, Unett DJ, Behan DP, Sadeque A, Usmani KA, Chen C, Edwards J, Morgan M, Jones RM.

Bioorg Med Chem Lett. 2015 Jan 15;25(2):322-6. doi: 10.1016/j.bmcl.2014.11.040. Epub 2014 Nov 26.

PMID:
25488844
13.

Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.

Lauring B, Taggart AK, Tata JR, Dunbar R, Caro L, Cheng K, Chin J, Colletti SL, Cote J, Khalilieh S, Liu J, Luo WL, Maclean AA, Peterson LB, Polis AB, Sirah W, Wu TJ, Liu X, Jin L, Wu K, Boatman PD, Semple G, Behan DP, Connolly DT, Lai E, Wagner JA, Wright SD, Cuffie C, Mitchel YB, Rader DJ, Paolini JF, Waters MG, Plump A.

Sci Transl Med. 2012 Aug 22;4(148):148ra115. doi: 10.1126/scitranslmed.3003877.

14.

(1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans.

Boatman PD, Lauring B, Schrader TO, Kasem M, Johnson BR, Skinner P, Jung JK, Xu J, Cherrier MC, Webb PJ, Semple G, Sage CR, Knudsen J, Chen R, Luo WL, Caro L, Cote J, Lai E, Wagner J, Taggart AK, Carballo-Jane E, Hammond M, Colletti SL, Tata JR, Connolly DT, Waters MG, Richman JG.

J Med Chem. 2012 Apr 26;55(8):3644-66. doi: 10.1021/jm2010964. Epub 2012 Apr 9.

PMID:
22435740
15.

Identification of fused bicyclic heterocycles as potent and selective 5-HT(2A) receptor antagonists for the treatment of insomnia.

Xiong Y, Ullman B, Choi JS, Cherrier M, Strah-Pleynet S, Decaire M, Feichtinger K, Frazer JM, Yoon WH, Whelan K, Sanabria EK, Grottick AJ, Al-Shamma H, Semple G.

Bioorg Med Chem Lett. 2012 Mar 1;22(5):1870-3. doi: 10.1016/j.bmcl.2012.01.080. Epub 2012 Jan 28.

PMID:
22325948
16.

Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile.

Semple G, Lehmann J, Wong A, Ren A, Bruce M, Shin YJ, Sage CR, Morgan M, Chen WC, Sebring K, Chu ZL, Leonard JN, Al-Shamma H, Grottick AJ, Du F, Liang Y, Demarest K, Jones RM.

Bioorg Med Chem Lett. 2012 Feb 15;22(4):1750-5. doi: 10.1016/j.bmcl.2011.12.092. Epub 2011 Dec 30.

PMID:
22264481
17.

Identification of biaryl sulfone derivatives as antagonists of the histamine H₃ receptor: discovery of (R)-1-(2-(4'-(3-methoxypropylsulfonyl)biphenyl-4-yl)ethyl)-2-methylpyrrolidine (APD916).

Semple G, Santora VJ, Smith JM, Covel JA, Hayashi R, Gallardo C, Ibarra JB, Schultz JA, Park DM, Estrada SA, Hofilena BJ, Smith BM, Ren A, Suarez M, Frazer J, Edwards JE, Hart R, Hauser EK, Lorea J, Grottick AJ.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):71-5. doi: 10.1016/j.bmcl.2011.11.075. Epub 2011 Nov 30.

PMID:
22172695
18.

International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B).

Offermanns S, Colletti SL, Lovenberg TW, Semple G, Wise A, IJzerman AP.

Pharmacol Rev. 2011 Jun;63(2):269-90. doi: 10.1124/pr.110.003301. Epub 2011 Mar 31. Review.

PMID:
21454438
19.

Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control.

Semple G, Ren A, Fioravanti B, Pereira G, Calderon I, Choi K, Xiong Y, Shin YJ, Gharbaoui T, Sage CR, Morgan M, Xing C, Chu ZL, Leonard JN, Grottick AJ, Al-Shamma H, Liang Y, Demarest KT, Jones RM.

Bioorg Med Chem Lett. 2011 May 15;21(10):3134-41. doi: 10.1016/j.bmcl.2011.03.007. Epub 2011 Mar 13.

PMID:
21444206
20.

Synthesis and in vivo evaluation of phenethylpiperazine amides: selective 5-hydroxytryptamine(2A) receptor antagonists for the treatment of insomnia.

Xiong Y, Ullman B, Choi JS, Cherrier M, Strah-Pleynet S, Decaire M, Dosa PI, Feichtinger K, Teegarden BR, Frazer JM, Yoon WH, Shan Y, Whelan K, Hauser EK, Grottick AJ, Semple G, Al-Shamma H.

J Med Chem. 2010 Aug 12;53(15):5696-706. doi: 10.1021/jm100479q.

PMID:
20684606
21.

Discovery and structure-activity relationship of 3-methoxy-N-(3-(1-methyl-1H-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide (APD791): a highly selective 5-hydroxytryptamine2A receptor inverse agonist for the treatment of arterial thrombosis.

Xiong Y, Teegarden BR, Choi JS, Strah-Pleynet S, Decaire M, Jayakumar H, Dosa PI, Casper MD, Pham L, Feichtinger K, Ullman B, Adams J, Yuskin D, Frazer J, Morgan M, Sadeque A, Chen W, Webb RR, Connolly DT, Semple G, Al-Shamma H.

J Med Chem. 2010 Jun 10;53(11):4412-21. doi: 10.1021/jm100044a.

PMID:
20455563
23.

Potent tricyclic pyrazole tetrazole agonists of the nicotinic acid receptor (GPR109a).

Boatman PD, Schrader TO, Kasem M, Johnson BR, Skinner PJ, Jung JK, Xu J, Cherrier MC, Webb PJ, Semple G, Sage CR, Knudsen J, Chen R, Taggart AK, Carballo-Jane E, Richman JG.

Bioorg Med Chem Lett. 2010 May 1;20(9):2797-800. doi: 10.1016/j.bmcl.2010.03.062. Epub 2010 Mar 20.

PMID:
20363624
24.

Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.

Semple G, Tran TA, Kramer B, Hsu D, Han S, Choi J, Vallar P, Casper MD, Zou N, Hauser EK, Thomsen W, Whelan K, Sengupta D, Morgan M, Sekiguchi Y, Kanuma K, Chaki S, Grottick AJ.

Bioorg Med Chem Lett. 2009 Nov 1;19(21):6166-71. doi: 10.1016/j.bmcl.2009.09.003. Epub 2009 Sep 6.

PMID:
19773162
25.

Design and evaluation of novel biphenyl sulfonamide derivatives with potent histamine H(3) receptor inverse agonist activity.

Covel JA, Santora VJ, Smith JM, Hayashi R, Gallardo C, Weinhouse MI, Ibarra JB, Schultz JA, Park DM, Estrada SA, Hofilena BJ, Pulley MD, Smith BM, Ren A, Suarez M, Frazer J, Edwards J, Hauser EK, Lorea J, Semple G, Grottick AJ.

J Med Chem. 2009 Sep 24;52(18):5603-11. doi: 10.1021/jm900857n.

PMID:
19722526
26.

Solubilized phenyl-pyrazole ureas as potent, selective 5-HT(2A) inverse-agonists and their application as antiplatelet agents.

Dosa PI, Strah-Pleynet S, Jayakumar H, Casper M, Decaire M, Xiong Y, Lehmann J, Choi K, Elwell K, Wong A, Webb RR, Adams JW, Ramirez J, Richman JG, Thomsen W, Semple G, Teegarden BR.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5486-9. doi: 10.1016/j.bmcl.2009.07.073. Epub 2009 Jul 18.

PMID:
19665894
27.

5-N,N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b.

Skinner PJ, Webb PJ, Sage CR, Dang TH, Pride CC, Chen R, Tamura SY, Richman JG, Connolly DT, Semple G.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4207-9. doi: 10.1016/j.bmcl.2009.05.108. Epub 2009 May 30.

PMID:
19524438
28.

New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists.

Yea CM, Allan CE, Ashworth DM, Barnett J, Baxter AJ, Broadbridge JD, Franklin RJ, Hampton SL, Hudson P, Horton JA, Jenkins PD, Penson AM, Pitt GR, Rivière P, Robson PA, Rooker DP, Semple G, Sheppard A, Haigh RM, Roe MB.

J Med Chem. 2008 Dec 25;51(24):8124-34. doi: 10.1021/jm8008162.

PMID:
19053774
29.

Nicotinic acid receptor agonists.

Boatman PD, Richman JG, Semple G.

J Med Chem. 2008 Dec 25;51(24):7653-62. doi: 10.1021/jm800896z. Review. No abstract available.

PMID:
18983141
30.

Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans.

Lai E, Waters MG, Tata JR, Radziszewski W, Perevozskaya I, Zheng W, Wenning L, Connolly DT, Semple G, Johnson-Levonas AO, Wagner JA, Mitchel Y, Paolini JF.

J Clin Lipidol. 2008 Oct;2(5):375-83. doi: 10.1016/j.jacl.2008.08.445. Epub 2008 Aug 23.

PMID:
21291763
31.

Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.

Semple G, Fioravanti B, Pereira G, Calderon I, Uy J, Choi K, Xiong Y, Ren A, Morgan M, Dave V, Thomsen W, Unett DJ, Xing C, Bossie S, Carroll C, Chu ZL, Grottick AJ, Hauser EK, Leonard J, Jones RM.

J Med Chem. 2008 Sep 11;51(17):5172-5. doi: 10.1021/jm8006867. Epub 2008 Aug 13.

PMID:
18698756
32.

3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice.

Semple G, Skinner PJ, Gharbaoui T, Shin YJ, Jung JK, Cherrier MC, Webb PJ, Tamura SY, Boatman PD, Sage CR, Schrader TO, Chen R, Colletti SL, Tata JR, Waters MG, Cheng K, Taggart AK, Cai TQ, Carballo-Jane E, Behan DP, Connolly DT, Richman JG.

J Med Chem. 2008 Aug 28;51(16):5101-8. doi: 10.1021/jm800258p. Epub 2008 Jul 30.

PMID:
18665582
33.

Novel H3 receptor antagonists with improved pharmacokinetic profiles.

Santora VJ, Covel JA, Hayashi R, Hofilena BJ, Ibarra JB, Pulley MD, Weinhouse MI, Semple G, Ren A, Pereira G, Edwards JE, Suarez M, Frazer J, Thomsen W, Hauser E, Lorea J, Grottick AJ.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):4133-6. doi: 10.1016/j.bmcl.2008.05.086. Epub 2008 May 24.

PMID:
18554904
34.

A new family of H3 receptor antagonists based on the natural product Conessine.

Santora VJ, Covel JA, Hayashi R, Hofilena BJ, Ibarra JB, Pulley MD, Weinhouse MI, Sengupta D, Duffield JJ, Semple G, Webb RR, Sage C, Ren A, Pereira G, Knudsen J, Edwards JE, Suarez M, Frazer J, Thomsen W, Hauser E, Whelan K, Grottick AJ.

Bioorg Med Chem Lett. 2008 Feb 15;18(4):1490-4. doi: 10.1016/j.bmcl.2007.12.059. Epub 2007 Dec 25.

PMID:
18194865
35.

3-Nitro-4-amino benzoic acids and 6-amino nicotinic acids are highly selective agonists of GPR109b.

Skinner PJ, Cherrier MC, Webb PJ, Sage CR, Dang HT, Pride CC, Chen R, Tamura SY, Richman JG, Connolly DT, Semple G.

Bioorg Med Chem Lett. 2007 Dec 1;17(23):6619-22. Epub 2007 Sep 19.

PMID:
17931863
36.

Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109a.

Skinner PJ, Cherrier MC, Webb PJ, Shin YJ, Gharbaoui T, Lindstrom A, Hong V, Tamura SY, Dang HT, Pride CC, Chen R, Richman JG, Connolly DT, Semple G.

Bioorg Med Chem Lett. 2007 Oct 15;17(20):5620-3. Epub 2007 Aug 23.

PMID:
17804224
37.

Recent progress in the discovery of niacin receptor agonists.

Semple G, Boatman PD, Richman JG.

Curr Opin Drug Discov Devel. 2007 Jul;10(4):452-9. Review.

PMID:
17659487
38.

Agonist lead identification for the high affinity niacin receptor GPR109a.

Gharbaoui T, Skinner PJ, Shin YJ, Averbuj C, Jung JK, Johnson BR, Duong T, Decaire M, Uy J, Cherrier MC, Webb PJ, Tamura SY, Zou N, Rodriguez N, Boatman PD, Sage CR, Lindstrom A, Xu J, Schrader TO, Smith BM, Chen R, Richman JG, Connolly DT, Colletti SL, Tata JR, Semple G.

Bioorg Med Chem Lett. 2007 Sep 1;17(17):4914-9. Epub 2007 Jun 10.

PMID:
17588745
39.

Nicotinic acid receptor agonists differentially activate downstream effectors.

Richman JG, Kanemitsu-Parks M, Gaidarov I, Cameron JS, Griffin P, Zheng H, Guerra NC, Cham L, Maciejewski-Lenoir D, Behan DP, Boatman D, Chen R, Skinner P, Ornelas P, Waters MG, Wright SD, Semple G, Connolly DT.

J Biol Chem. 2007 Jun 22;282(25):18028-36. Epub 2007 Apr 23.

40.

Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b.

Jung JK, Johnson BR, Duong T, Decaire M, Uy J, Gharbaoui T, Boatman PD, Sage CR, Chen R, Richman JG, Connolly DT, Semple G.

J Med Chem. 2007 Apr 5;50(7):1445-8. Epub 2007 Mar 15.

PMID:
17358052
41.

A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.

Chu ZL, Jones RM, He H, Carroll C, Gutierrez V, Lucman A, Moloney M, Gao H, Mondala H, Bagnol D, Unett D, Liang Y, Demarest K, Semple G, Behan DP, Leonard J.

Endocrinology. 2007 Jun;148(6):2601-9. Epub 2007 Feb 8. Erratum in: Endocrinology. 2007 Oct;148(10):4753.

PMID:
17289847
42.

ATC0175: an orally active melanin-concentrating hormone receptor 1 antagonist for the potential treatment of depression and anxiety.

Chaki S, Yamaguchi J, Yamada H, Thomsen W, Tran TA, Semple G, Sekiguchi Y.

CNS Drug Rev. 2005 Winter;11(4):341-52. Review.

43.

1-Alkyl-benzotriazole-5-carboxylic acids are highly selective agonists of the human orphan G-protein-coupled receptor GPR109b.

Semple G, Skinner PJ, Cherrier MC, Webb PJ, Sage CR, Tamura SY, Chen R, Richman JG, Connolly DT.

J Med Chem. 2006 Feb 23;49(4):1227-30.

PMID:
16480258
44.

Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists.

Kanuma K, Omodera K, Nishiguchi M, Funakoshi T, Chaki S, Nagase Y, Iida I, Yamaguchi J, Semple G, Tran TA, Sekiguchi Y.

Bioorg Med Chem. 2006 May 15;14(10):3307-19. Epub 2006 Jan 24.

PMID:
16434202
45.

Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1.

Kanuma K, Omodera K, Nishiguchi M, Funakoshi T, Chaki S, Semple G, Tran TA, Kramer B, Hsu D, Casper M, Thomsen B, Sekiguchi Y.

Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6.

PMID:
16002290
46.

Discovery of 4-(dimethylamino)quinazolines as potent and selective antagonists for the melanin-concentrating hormone receptor 1.

Kanuma K, Omodera K, Nishiguchi M, Funakoshi T, Chaki S, Semple G, Tran TA, Kramer B, Hsu D, Casper M, Thomsen B, Beeley N, Sekiguchi Y.

Bioorg Med Chem Lett. 2005 May 16;15(10):2565-9.

PMID:
15863317
47.

Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists.

Chaki S, Funakoshi T, Hirota-Okuno S, Nishiguchi M, Shimazaki T, Iijima M, Grottick AJ, Kanuma K, Omodera K, Sekiguchi Y, Okuyama S, Tran TA, Semple G, Thomsen W.

J Pharmacol Exp Ther. 2005 May;313(2):831-9. Epub 2005 Jan 26.

PMID:
15677346
48.

Clinically validated peptides as templates for de novo peptidomimetic drug design at G-protein-coupled receptors.

Jones RM, Boatman PD, Semple G, Shin YJ, Tamura SY.

Curr Opin Pharmacol. 2003 Oct;3(5):530-43. Review.

PMID:
14559100
49.

Synthesis and Biological activity of kappa opioid receptor agonists. Part 2: preparation of 3-aryl-2-pyridone analogues generated by solution- and solid-phase parallel synthesis methods.

Semple G, Andersson BM, Chhajlani V, Georgsson J, Johansson MJ, Rosenquist A, Swanson L.

Bioorg Med Chem Lett. 2003 Mar 24;13(6):1141-5.

PMID:
12643930
50.

3-Aryl pyridone derivatives. Potent and selective kappa opioid receptor agonists.

Semple G, Andersson BM, Chhajlani V, Georgsson J, Johansson M, Lindschoten M, Pontén F, Rosenquist A, Sörensen H, Swanson L, Swanson M.

Bioorg Med Chem Lett. 2002 Jan 21;12(2):197-200.

PMID:
11755353

Supplemental Content

Loading ...
Support Center